Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Deodhar, Atul; Gottlieb, Alice B; Boehncke, Wolf-Henning; Dong, Bin; Wang, Yuhua; Zhuang, Yanli; Barchuk, William; Xu, Xie L; Hsia, Elizabeth C; CNTO1959PSA2001 Study Group

doi:10.1016/S0140-6736(18)30952-8

Scientific article

English

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

ContributorsDeodhar, Atul; Gottlieb, Alice B; Boehncke, Wolf-Henning; Dong, Bin; Wang, Yuhua; Zhuang, Yanli; Barchuk, William; Xu, Xie L; Hsia, Elizabeth C; CNTO1959PSA2001 Study Group

Published inThe Lancet, vol. 391, no. 10136, p. 2213-2224

Publication date2018

Abstract

Guselkumab, a human monoclonal antibody that binds to the p19 subunit of interleukin 23, has been approved for the treatment of moderate-to-severe psoriasis. Psoriatic arthritis is a common comorbidity of psoriasis with an umet need for novel treatments. We assessed the efficacy and safety of guselkumab in patients with active psoriatic arthritis.

Keywords

Adult
Aged
Antibodies
Monoclonal/therapeutic use
Arthritis
Psoriatic/drug therapy
Double-Blind Method
Female
Humans
Immunologic Factors/therapeutic use
Injections
Subcutaneous
Interleukin-23 Subunit p19
Male
Middle Aged
Treatment Outcome

Affiliation entities

Research groups

Mécanismes des pathologies de l'inflammation cutanée (919)

Citation (ISO format)

DEODHAR, Atul et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. In: The Lancet, 2018, vol. 391, n° 10136, p. 2213–2224. doi: 10.1016/S0140-6736(18)30952-8

Article (Published version)

Identifiers

PID : unige:125829
DOI : 10.1016/S0140-6736(18)30952-8
PMID : 29893222

Commercial URLhttps://www.sciencedirect.com/science/article/pii/S0140673618309528

Journal ISSN0140-6736

268views

0downloads

Creation12/08/2019 12:53:00

First validation12/08/2019 12:53:00

Update time15/03/2023 18:18:56

Status update15/03/2023 18:18:55

Last indexation31/10/2024 16:48:56

Archive ouverte UNIGE

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Technical informations